Pancreatic Cancer Incidence Has Risen, Yet Survival Outcomes Have Improved

Commentary
Video

Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.

As part of Pancreatic Cancer Awareness Month, Mehmet Sitki Copur, MD, FACP, spoke with CancerNetwork® about current data related to pancreatic cancer incidence and survival outcomes.

According to Copur, a medical director of Oncology and adjunct professor of Medical Oncology/Hematology at the University of Nebraska Medical Center, a medical oncologist/hematologist at Morrison Cancer Center of Mary Lanning Healthcare, and gastrointestinal editorial advisory board member for the journal ONCOLOGY, pancreatic cancer is approximately the eighth to tenth most common cancer diagnosis in 2024. However, the incidence of this disease is projected to rise; by 2030, pancreatic cancer is anticipated to become the second-leading cause of cancer-related death across the US. Regardless, Copur noted that the 5-year survival rate among patients with pancreatic cancer has improved since the 1970s.

Transcript:

[Pancreatic cancer] used to be a rare cancer and a deadly cancer with no treatments. Right now, it is the eighth to tenth most common cancer and 3% of all new cancers as of 2024, and new diagnoses are expected to be [approximately] 66,000 [in 2024]. What is so important about this disease, even though it’s [currently] the eighth or tenth most common [disease], it is almost on its way to becoming the [second-leading cause of cancer-related death]. The [first-leading cancer] for many years has been lung [cancer], with 160,000 deaths a year. Pancreatic cancer used to be in the third, fourth, or fifth range. Now, as of 2020, it reached up to the colorectal cancer death rate, and they are expecting, by 2030, that pancreatic cancer will be the [second-leading cause of cancer-related death]. The reason for this is that it has been notoriously resistant to available treatments.

During my fellowship, pancreatic cancer was like a death sentence. Over the decades, the 5-year survival was only 2% back in the 1970s. Now, it came up to 7% as of 2024. The most recent Pancreatic Cancer Action Network presentation gave us an optimistic number of 12% of 5-year survival, which is unheard of in this disease.

Epidemiology

Epidemiology

Projected Cancer-Related Deaths

Projected Cancer-Related Deaths

Trends in 5-year cancer survival

Trends in 5-year cancer survival

5-year pancreatic cancer survival

5-year pancreatic cancer survival

All images are posted with the permission of Mehmet Sitki Copur, MD, FACP.

Reference

Pancreatic cancer facts. Hirshberg Foundation for Pancreatic Cancer Research. Accessed November 21, 2024. https://tinyurl.com/mrpf34j2

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content